Vol.

No.

March 15, 2019Mar 15, 2019

DOWNLOAD THE PDF

The Gottlieb-Sharpless-Lowy rearrangement

Cover Story

News Analysis

The Gottlieb-Sharpless-Lowy rearrangement

By Paul Goldberg

No prizes should be handed out to anyone who predicted that:

Free

Trump proposal for FY2020 to slash NIH by 12 percent, NCI by 15 percent

By Claire Dietz and Matthew Bin Han Ong

DuBois to receive Magaret Foti award; Freireich–Lifetime Achievement award; Hudson and Robison–Team Science award

Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture

Clinical Conversation with The Cancer Letter Free

TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”

By Paul Goldberg

In Brief

Fred Hirsch to join Mount Sinai Tisch Cancer Institute

Reps. Higgins, Guthrie, Matsui and Bilirakis announce the Cancer Drug Parity Act

Ong named a finalist in the 25th Annual NIHCM Research and Journalism Awards

Clinical Roundup

UAMS study shows potential to alter neck dissection surgery in head and neck cancer

Drugs & Targets

European Commission approves Keytruda + chemotherapy for NSCLC

Tecentriq + Abraxane regimen gets accelerated approval for breast cancer

Trazimera, Herceptin biosimilar, gets FDA approval

myPath melanoma test receives Medicare coverage

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 07 - February 21, 2025

The Gottlieb-Sharpless-Lowy rearrangement

Trump proposal for FY2020 to slash NIH by 12 percent, NCI by 15 percent

DuBois to receive Magaret Foti award; Freireich–Lifetime Achievement award; Hudson and Robison–Team Science award

Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture

TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”

In Brief

Fred Hirsch to join Mount Sinai Tisch Cancer Institute

Reps. Higgins, Guthrie, Matsui and Bilirakis announce the Cancer Drug Parity Act

Ong named a finalist in the 25th Annual NIHCM Research and Journalism Awards

Clinical Roundup

UAMS study shows potential to alter neck dissection surgery in head and neck cancer

Drugs & Targets

European Commission approves Keytruda + chemotherapy for NSCLC

Tecentriq + Abraxane regimen gets accelerated approval for breast cancer

Trazimera, Herceptin biosimilar, gets FDA approval

myPath melanoma test receives Medicare coverage

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login